Form 4: Longboard Pharmaceuticals Director Disposes of Stock Options Following Merger

Casey Lynch, a director at Longboard Pharmaceuticals, disposed of multiple employee stock options as a result of the company's merger with a subsidiary of H. Lundbeck A/S.

Summary

• This SEC Form 4 filing reports the changes in beneficial ownership of securities by Casey Lynch, a director at Longboard Pharmaceuticals.
• The filing details the disposal of several employee stock options held by Mr. Lynch following the completion of a merger on December 2, 2024.
• The merger resulted in the cancellation of unexercised vested options, which were converted into the right to receive cash.
• The cash payment was calculated as the difference between $60 per share and the exercise price of each option, multiplied by the number of shares subject to the option.
• The options had various exercise prices, including $16, $4.40, $7.06, and $18.94, and were set to expire between 2031 and 2034.

Sentiment

Score: 7

Explanation: The document is a standard SEC filing related to a merger, which is a neutral event. The sentiment is slightly positive as the merger has been completed.

Future Outlook

The merger has been completed, and Longboard Pharmaceuticals is now an indirect wholly-owned subsidiary of H. Lundbeck A/S.

Industry Context

This merger reflects a trend of pharmaceutical companies acquiring smaller biotech firms to expand their pipelines and capabilities.

Comparison to Industry Standards

• Mergers and acquisitions are common in the pharmaceutical industry, with larger companies often acquiring smaller firms with promising drug candidates.
• The valuation of $60 per share in this merger is a key metric to compare against other similar transactions in the biotech sector.
• Comparable transactions would include other acquisitions of clinical-stage biotech companies by larger pharmaceutical firms, where the premium paid over the pre-acquisition share price is a key point of comparison.

Stakeholder Impact

• Shareholders of Longboard Pharmaceuticals received $60 per share as part of the merger.
• Employees holding stock options received cash payments based on the difference between $60 and the exercise price of their options.

Key Dates

Keywords

Merger, Stock Options, Beneficial Ownership, SEC Form 4, Longboard Pharmaceuticals, Director, H. Lundbeck A/S, Lynch Casey